Dendritic cell (undefined molecular receptor) (DC)

Dendritic cells (DCs) are professional antigen-presenting cells that serve as the primary link between innate and adaptive immunity [2]. They function by capturing antigens from the environment, processing them into peptides, and presenting them on MHC molecules to T cells to initiate specific immune responses [1, 4]. The designation "Dendritic cells – undefined molecular receptor" refers to therapeutic interventions where the dendritic cell is the intended target, but the specific molecular receptor or binding site involved in the drug-cell interaction has not been definitively characterized [3]. This classification is frequently encountered in the development of complex biologics, such as ex vivo loaded DC vaccines like Sipuleucel-T, or early-stage immunomodulators where the precise molecular mechanism of action remains elusive [5]. Targeting DCs is a major strategy in cancer immunotherapy to promote anti-tumor T cell responses, as well as in the treatment of autoimmune diseases to induce immunological tolerance [2, 4]. Despite the lack of a defined molecular receptor in some cases, these therapies leverage the natural ability of DCs to migrate to lymphoid organs and orchestrate systemic immune activity [1]. Ongoing research aims to identify specific surface markers, such as C-type lectins or Toll-like receptors, to improve the precision of DC-targeted delivery systems [3].

Other names

Dendritic cellDCProfessional antigen-presenting cellAPC

Enhancement of antigen presentation and T cell priming